(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)
Description: 
This trial aims to establish whether patients with tumor mutations, amplifications or translocations in one of the genetic pathways of interest are likely to derive clinical benefit (primary objective: objective response; secondary objective: progression-free survival of at least 6 months) if treated with agents targeting that specific pathway in a single-arm design.
Study Number: 

NCG 275215

Phase: 
NA
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02465060

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.